Mounjaro® and the Ivím weight loss program

A weekly tirzepatide injection to improve insulin sensitivity, reduce appetite, and regulate blood sugar.*

Disclaimer: Mounjaro® is not FDA-approved for weight loss. It may be prescribed by an Ivím provider if deemed appropriate for your medical needs. For additional safety information, please see our Safety Page.

Mounjaro® (tirzepatide) injection is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist originally approved for the treatment of type 2 diabetes. It functions by mimicking a hormone that targets areas of the brain involved in appetite regulation.

Mounjaro® works by slowing gastric emptying, enhancing feelings of fullness, and reducing appetite, which can help manage weight when combined with diet and exercise.

How much Mounjaro® is with insurance depends on your insurance plan and whether Mounjaro® is prescribed for an FDA-approved use. Ivím Health offers a free initial consultation to navigate insurance or explore self-pay options.

Ivím Health offers weight management programs for patients. Mounjaro® is FDA approved for the management of Type 2 Diabetes and may be prescribed by an Ivím Health provider as part of your weight management program.

Choosing a GLP-1 medication like Mounjaro® depends on individual health history and insurance coverage. Your Ivím provider can help determine the best option for your weight loss journey.

*Disclaimer: Mounjaro® is a registered trademark of Eli Lilly. Ivím is not affiliated with Eli Lilly.